Product
Help
Pricing
About
Jobs
Log in
Get started
Keyword
Add to collection
dinaciclib
Description:
Dinaciclib is a small-molecule anticancer drug that inhibits cyclin-dependent kinases and has been investigated in cancer treatment.
Wikidata ID:
wiki/Q15723091
OpenAlex ID:
keywords/dinaciclib
Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor
2010
·
David Parry
, Timothy Guzi
, et al.
·
Molecular Cancer Therapeutics
·
606
PDF
Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance
2016
·
Ping Chen
, Nathan V. Lee
, et al.
·
Molecular Cancer Therapeutics
·
475
CDK inhibitors in cancer therapy, an overview of recent development.
2021
·
Mengna Zhang
, Lingxian Zhang
, et al.
·
PubMed
·
393
CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer
2016
·
Shawn F. Johnson
, Cristina Cruz
, et al.
·
Cell Reports
·
322
PDF
Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma
2014
·
Shaji K. Kumar
, Betsy LaPlant
, et al.
·
Blood
·
277
PDF
Kinome-Wide RNA Interference Screen Reveals a Role for PDK1 in Acquired Resistance to CDK4/6 Inhibition in ER-Positive Breast Cancer
2017
·
Valerie M. Jansen
, Neil E. Bhola
, et al.
·
Cancer Research
·
258
Dinaciclib induces immunogenic cell death and enhances anti-PD1–mediated tumor suppression
2018
·
Dewan Md Sakib Hossain
, Sarah Javaid
, et al.
·
Journal of Clinical Investigation
·
230
Overview of CDK9 as a target in cancer research
2016
·
Fatima Morales
, Antonio Giordano
·
Cell Cycle
·
217
PDF
Discovery of Dinaciclib (SCH 727965): A Potent and Selective Inhibitor of Cyclin-Dependent Kinases
2010
·
Kamil Paruch
, Michael P. Dwyer
, et al.
·
ACS Medicinal Chemistry Letters
·
202
Novel agents in the treatment of multiple myeloma: a review about the future
2016
·
Leonard Naymagon
, Maher Abdul-Hay
·
Journal of Hematology & Oncology
·
196
Targeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapy
2017
·
Akane Inoue-Yamauchi
, Paul S. Jeng
, et al.
·
Nature Communications
·
189
PDF
Tamoxifen-resistant breast cancer cells are resistant to DNA-damaging chemotherapy because of upregulated BARD1 and BRCA1
2018
·
Yinghua Zhu
, Yujie Liu
, et al.
·
Nature Communications
·
183
PDF
Therapeutic targeting of tumor-associated myeloid cells synergizes with radiation therapy for glioblastoma
2019
·
Peng Zhang
, Jason Miska
, et al.
·
Proceedings of the National Academy of Sciences
·
174
PDF
Cyclin-dependent kinase inhibitor therapy for hematologic malignancies
2013
·
Prithviraj Bose
, Gary L Simmons
, et al.
·
Expert Opinion on Investigational Drugs
·
168
Cyclin-Dependent Kinase Inhibitor Dinaciclib Interacts with the Acetyl-Lysine Recognition Site of Bromodomains
2013
·
Mathew P. Martin
, Sanne H. Olesen
, et al.
·
ACS Chemical Biology
·
167
Randomized Phase II Trial of the Cyclin-Dependent Kinase Inhibitor Dinaciclib (MK-7965) Versus Capecitabine in Patients With Advanced Breast Cancer
2013
·
Monica M. Mita
, Anil A. Joy
, et al.
·
Clinical Breast Cancer
·
166
Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition
2016
·
George Au-Yeung
, Franziska Lang
, et al.
·
Clinical Cancer Research
·
163
Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer
2017
·
Jason. P.W. Carey
, Cansu Karakas
, et al.
·
Cancer Research
·
160
CDK9 inhibition by dinaciclib potently suppresses Mcl-1 to induce durable apoptotic responses in aggressive MYC-driven B-cell lymphoma in vivo
2014
·
G P Gregory
, S J Hogg
, et al.
·
Leukemia
·
156
PDF
Tumor lysis syndrome in the era of novel and targeted agents in patients with hematologic malignancies: a systematic review
2016
·
Scott C. Howard
, Steven Trifilio
, et al.
·
Annals of Hematology
·
152
A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies
2013
·
John J Nemunaitis
, Karen A Small
, et al.
·
Journal of Translational Medicine
·
141
PDF
Targeting CDK1 and MEK/ERK Overcomes Apoptotic Resistance in BRAF-Mutant Human Colorectal Cancer
2017
·
Peng Zhang
, Hisato Kawakami
, et al.
·
Molecular Cancer Research
·
138
Regulated induced proximity targeting chimeras—RIPTACs—A heterobifunctional small molecule strategy for cancer selective therapies
2024
·
Kanak Raina
, Chris D. Forbes
, et al.
·
Cell chemical biology
·
133
Dinaciclib is a novel cyclin-dependent kinase inhibitor with significant clinical activity in relapsed and refractory chronic lymphocytic leukemia
2015
·
J Flynn
, J Jones
, et al.
·
Leukemia
·
133
CDK1/2/5 inhibition overcomes IFNG-mediated adaptive immune resistance in pancreatic cancer
2020
·
Jin Huang
, Pan Chen
, et al.
·
Gut
·
130
Show more works
View as search
Works count:
595
Citation count:
11,560
Year
Topic
Type